The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | The association between high blood sugar and CAR-T outcomes in multiple myeloma
Urvi Shah, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses findings from a metabolic-epigenetic study that identified high blood sugar as a modifiable risk factor for worse outcomes after CAR T-cell therapy in patients with multiple myeloma. Dr Shah explains that high blood sugar increases methylglyoxal (MGO) production, which drives T-cell exhaustion, with similar pathways seen in T-cells from patients with diabetes. She discusses two investigational approaches: engineering CAR T-cells to express the enzyme DJ-1 to reduce T-cell exhaustion and using metformin in patients with diabetes to improve T-cell function. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
